ArticleBMC gastroenterology2026
ETV4 as a potential target gene for alleviating proliferation metastasis of HCC.
Article in BMC gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundHepatocellular carcinoma (HCC) develops and progresses via the RAF/MERK/ERK signaling pathway. Sorafenib, a first-line therapy for advanced HCC, inhibits the RAF gene. However, RAF dimerization and ERK activation caused by RAF inhibition in HCC, and this paradoxical RAF/MERK/ERK activation is one of the reasons for Sorafenib resistance in liver cell carcinoma. ETV4 is an ERK downstream gene, hence inhibiting it may help to reduce treatment resistance in HCC. The human hepatoma cell line HepG2.2.15 was used as an HCC tumor cell model, while the HL-7702 cell line was used as a human normal hepatocytes cell model. In order to find out the function of ETV4, Small interfering RNA (siRNA) was used to knock down ETV4 gene. Experiments on cell phenotype and function were performed to test the effects of knocking down ETV4. MATERIALS AND
methodsThere were four groups in vitro: control group, siRNA-NC group, siRNA-ETV4 group and normal group. Cultured 5 × 10
resultsSilencing of ETV4 decreased RNA expression of ERK1, ERK2, MMP1, and MMP9, as well as the protein levels of p-ERK, MMP1, and MMP9. Cell proliferation, migration, and invasion were also reduced with low ETV4 expression. Furthermore, apoptosis of HCC cells increased in low expression of ETV4 group. HCC cells were obstructed in G2/M cell cycle phase and decreased quantity in the DNA preparation in the G0/G1 phase. Knockdown ETV4 decreased KI67 and Vimentin in the tumor tissues, while the protein level of E-cadherin was significantly increased. ETV4 enriched at the MMP1-EBS3 and MMP9-EBS4 regions in HCC.
conclusionETV4 is a key gene connecting the RAF/MER/ERK pathway and the MMP family in tumor growth and development, especially in HCC. This study provides functional and mechanistic evidence suggesting that ETV4 knockdown limits the progression of HCC. This effect is mediated by the reduction of tumor cell proliferation and migration, which may occur, at least in part, through the modulation of the ERK/ETV4/MMPs axis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.